A5048541226- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Renal Transplantation Outcomes and Treatments
- Transplantation: Methods and Outcomes
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cardiac electrophysiology and arrhythmias
- Multiple and Secondary Primary Cancers
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology
2024
Ministry of Health of the Russian Federation
2024
Medical Technologies (Czechia)
2014
Istanbul University-Cerrahpaşa
2011
Therapeutic landscape of several genitourinary malignancies has been revolutionized by the development immune checkpoint inhibitors; however, utility immunotherapies in prostate cancer limited, partly due to immunologically “cold” tumor microenvironment cancer. As today, pembrolizumab is only inhibitor approved for treatment metastatic castration-resistant (mCRPC) a select group patients with high microsatellite instability, deficient mismatch repair, or mutational burden. Currently,...
<h3>Introduction</h3> Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD). Strategies to increase donor organ availability and prolong transplanted kidney9s survival have become priorities in kidney transplantation. Standard immunosuppressive therapy consists initial maintenance regimes prevent rejection short courses more intensive treat episodes acute rejection. Immunosuppressive drugs may cause electrocardiographic changes as increased...
Objective: an assessment of efficacy and safety lenvatinib in combination with everolimus unselected patients metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line antiangiogenic targeted therapy. Material. Russian multicenter observational study ROSLERCM included 73 consecutive morphologically verified mRCC therapy, treated (18 mg/d) (5 20 centers. Median age the was 59 (23–73) years, a male-to-female ratio – 3:1. Most common histological type kidney cancer...
The paper reviews the literature on treatment of renal cancer, mainly postoperative immunotherapy. It outlines a role cytokines in tumor-immune system interaction, prognostic value level expression each cytokine for both survival rates and efficiency immunotherapy, as well use this information to develop new therapeutic approaches.